
Medical Cannabis Provides Effective Relief From Migraine, Study Suggests
Nathaniel M. Schuster, a pain and headache neurologist and the lead investigator on the research, said the study's findings are significant.
'This is the first placebo-controlled study in this space. It's the first real — to me — compelling evidence for the antimigraine effects of cannabis in humans,' he said.
The study of 92 migraine patients compared the use of vaporized cannabis flower containing either THC or both THC and CBD to a placebo. The research found that subjects who used cannabis were more likely to report pain relief after two hours than those who took a placebo.
The data showed that after two hours, 68.9% of migraine patients who used THC cannabis and 67.2% who used marijuana with a combination of THC and CBD reported pain relief, compared to 46.6% of those who took a placebo. Just over half (52.6%) of those who used cannabis with only CBD reported relief, although the researchers did not find the difference compared to placebo to be statistically significant, Marijuana Moment reported.
Cannabis Was An Effective Treatment For Sensitivity To Light And Sound
Schuster said that the researchers initially had concerns that the effect cannabis had on some of migraine sufferers' most bothersome symptoms, such as sensitivity to light (photophobia) and sound (phonophobia), might be caused primarily by nausea relief instead of a broader response to migraine symptoms.
'That's certainly not what we found. What we found is that it does have effects on the photophobia and phonophobia, and that's an important finding,' he said.
Amaal J. Starling, MD, associate professor of neurology at the Mayo Clinic in Phoenix, told Medscape Medical News, that the efficacy and safety of cannabis as a treatment for migraine are not well understood.
'Even though THC/CBD use for the treatment of migraine is a popular topic for patients, there is a paucity of robust clinical trials on this topic. However, people are using cannabis to treat migraine and migraine symptoms, like nausea,' she said.
Cannabis And Migraine
Previous research has also shown that cannabis may be an effective treatment for migraine. A study published in 2020 showed that cannabis was a more effective treatment for migraine than standard pharmaceutical treatments. Separate research published in 2021 showed that data from a clinically validated survey showed that 86% of respondents reported a decrease in headache impact after using a CBD formulation for a 30-day trial period.
Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws (NORML), said the new study is consistent with the reported use of cannabis among migraine patients.
'Nearly one-third of migraine sufferers have tried cannabis for symptom management, and patients consistently report that it significantly reduces their pain severity and migraine frequency,' Armentano said in a statement from cannabis policy reform advocacy group. 'These data further affirm patients' testimonials.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
BRISBANE, Calif., August 06, 2025--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. "Nathan's deep financial expertise in molecular diagnostics is a great fit for CareDx," said John Hanna, CEO of CareDx. "His track record of operational excellence and experience in supporting diagnostics companies to scale efficiently will be invaluable as we enter our next phase." In conjunction with this appointment, the Company also announced that Abhishek Jain will be retiring from his role as Chief Financial Officer. Abhishek will continue to support CareDx in a consulting capacity to ensure a seamless transition. "On behalf of the Board and the entire CareDx team, I want to express my sincere gratitude to Abhishek for his outstanding leadership as CFO," said John Hanna. "Abhishek's disciplined financial management, stewardship through our CEO transition, and dedication to strengthening our finance function have positioned CareDx for continued success. We wish him all the best." About CareDx CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit Forward Looking Statements This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx's filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed by CareDx with the SEC on April 30, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts CareDx Media Contacts Natasha Moshirian Wagnernwagner@ Investor RelationsCaroline Cornerinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.


CBS News
7 minutes ago
- CBS News
Baltimore organizations try to keep the momentum going with overdose prevention
Some Baltimore organizations are working around the clock to combat drug abuse while trying to prevent residents from overdosing. The Pride Center of Maryland's Harm Reduction Team was in action on Wednesday in the city's Old Gaucher neighborhood, handing out resources, including Narcan. Those getting this help say this work is sorely needed, adding it's a life-or-death situation. Every day, members of the Pride Center of Maryland's Harm Reduction Team are outside the nonprofit's resource center on Maryland Avenue. They're sitting at tables, which are filled with food, hygiene products, clothes -- as well as Narcan, fentanyl strips, and other health resources. It's free for anyone who walks by. Jerome Scott, the Pride Center's program manager of wellness, said the purpose is about visibility and to let people know they are here to help. "[Let people know] we see you, we care, and we have things for you," Scott said. "We just like to let our faces be known." But, they aren't just stationary. Scott packed a few drawstring bags with what was on the tables and walked several blocks around the neighborhood, handing them out to anyone he saw. A volunteer also handed out lunches alongside him. Scott said there are times he would leave Narcan and other resources in certain locations, even if no one is there, so it can be readily accessible if someone were to use it nearby. Scott stressed that it's important this work doesn't lose momentum. "These are our brothers, these are our sisters, our aunts, our uncles out here. So, we wanna be there for them," Scott said. Scott said the mass overdoses in the Penn North neighborhood in July show why this work can't slow down. Penn North is another neighborhood where Scott does outreach and brings resources to. Jessica Collins, who received some of the Pride Center's free resources, said she's also been in an addiction treatment center since May. She said these resources need to be more accessible to encourage addicts to get help. "It's just each individual taking that step to go forward to wanting that that person making that decision to want to get help," Collins said. When asked how much Narcan his team has on hand, Scott said they try to have at least 500. However, the team goes through its inventory often, especially in the summer months.